Product
Inebilizumab
8 clinical trials
5 indications
Indication
Neuromyelitis Optica Spectrum DisordersIndication
Neuromyelitis Optica Spectrum DisorderIndication
IgG4-related diseaseIndication
systemic sclerosisClinical trial
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)Status: Not yet recruiting, Estimated PCD: 2024-12-25
Clinical trial
An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderStatus: Recruiting, Estimated PCD: 2027-04-13
Clinical trial
A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-04-09
Clinical trial
Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis (Placebo-Controlled Double-Blind Study)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicentric, Retrospective, Real-Word Study to Evaluate the Efficacy and Safety of Inebilizumab Compare With Rituximab in Neuromyelitis Optica Spectrum DisordersStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
Effectiveness and Safety of Inebilizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Prospective, Real Word StudyStatus: Not yet recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2 Open-label, Prospective, Randomized Study of Inebilizumab, VIB4920, or the Combination to Evaluate Safety and Tolerability in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorStatus: Withdrawn, Estimated PCD: 2021-12-01